Literature DB >> 17480018

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Joel R Rosh1, Thomas Gross, Petar Mamula, Anne Griffiths, Jeffrey Hyams.   

Abstract

Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL)-a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17480018     DOI： 10.1002/ibd.20169

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


  53 in total

Review 1.  [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

2.  Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

Authors:  Anna K Wong; Susan Kerkoutian; Jonathan Said; Hooman Rashidi; Sheeja T Pullarkat
Journal:  Clin Rheumatol       Date:  2011-11-18       Impact factor: 2.980

3.  Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model.

Authors:  Lily Nahidi; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  J Gastroenterol       Date:  2011-09-28       Impact factor: 7.527

4.  [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009].

Authors:  G Horneff; T Hospach; G Dannecker; D Föll; J P Haas; H J Girschick; H I Huppertz; R Keitzer; H J Laws; H Michels; K Minden; R Trauzeddel
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 5.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 6.  Probiotics in pediatric inflammatory bowel diseases.

Authors:  Ajay S Gulati; Marla C Dubinsky
Journal:  Curr Gastroenterol Rep       Date:  2009-06

Review 7.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 8.  Pediatric non-Hodgkin's lymphoma.

Authors:  Thomas G Gross; Amanda M Termuhlen
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

9.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

10.  A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Authors:  Elaheh Vahabnezhad; Shervin Rabizadeh; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.